BayCom (BCML) Q3 2024 earnings summary

Executive summary

• Clinical-stage biopharma with five clinical-stage assets in precision psychiatry, focusing on MDD, bipolar depression, and schizophrenia, all using brain-based biomarkers.

• ALTO-100 Phase 2b in MDD did not meet its primary endpoint; bipolar depression study continues with Wellcome Trust funding.

• Ongoing Phase 2b and POC trials for ALTO-100, ALTO-300, ALTO-203, and ALTO-101, with topline data expected 2025–2026.

• No product revenue to date; operations funded by $275.6M in equity and debt, including $133M net IPO proceeds in February 2024.

• Net loss of $16.8M for Q3 2024 and $46.2M for the nine months ended September 30, 2024; accumulated deficit of $123.2M.

Financial highlights

• Cash, cash equivalents, and restricted cash totaled $182.2M as of September 30, 2024, up from $82.5M at year-end 2023.

• Q3 2024 net loss was $16.8M, compared to $9.1M in Q3 2023; nine-month net loss was $46.2M, up from $25.1M year-over-year.

• Research and development expenses rose to $13.1M in Q3 2024 and $36.2M for the nine months, driven by clinical trial activity and personnel costs.

• General and administrative expenses increased to $5.8M in Q3 2024 and $15.4M for the nine months, reflecting public company costs and headcount growth.

• Interest income rose to $2.5M in Q3 2024, reflecting higher cash balances; interest expense was $0.3M for the quarter.

Outlook and guidance

• Cash runway expected to fund operations into 2027, based on current plans and spending assumptions.

• Substantial additional capital will be needed to complete clinical development and pursue commercialization.

• Topline data for ALTO-300 and ALTO-203 expected in 1H 2025, ALTO-101 in 2H 2025, and ALTO-100 (bipolar depression) in 2026.